Clinical Trial Update: Zevalin® First Line in Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Zevalin (ibritumomab tiuxetan) as first-line therapy for Follicular Lymphoma; no results or current status are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Follicular Lymphoma | Phase 2 | Status: UNKNOWN